Lv52
1128 积分 2025-12-04 加入
First-line FOLFOXIRI-based Chemotherapy for Unresectable Metastatic Colorectal Cancer: Real-world Outcomes, Safety, and Conversion Surgery
6天前
已完结
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial
7天前
已关闭
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
7天前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
14天前
已完结
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
27天前
已完结
Metastatic colorectal cancer: mechanisms and emerging therapeutics
28天前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
28天前
已完结
Colorectal cancer
28天前
已完结
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study
1个月前
已完结
皖公网安备34019202002308
